For decades, digital systems in life sciences have been designed primarily to support scientists through analysis and automation. Statistical models predicted outcomes, databases stored clinical records, and workflow tools enforced process steps. But in development, decisions are rarely made from a single dataset. They draw on protocols, historical evidence, regulatory expectations, operational realities, and human judgment.
Agentic AI changes this relationship. Agentic AI's near-term value comes from helping experts navigate increasingly complex workflows, coordinate fragmented information, and execute work more efficiently – while keeping responsibility for scientific decisions firmly with people. These systems are designed to retrieve information, coordinate tasks, aggregate and assemble evidence, surface risks and inconsistencies, and recommend next steps under human guidance. They prepare work, manage dependencies, and highlight what requires expert attention. Current excitement around agentic AI risks creating unrealistic expectations. In the near term, the technology is most valuable when helping experts navigate complex development environments where information is fragmented between systems, functions, and stakeholders, not when asked to make autonomous scientific decisions.
Agentic AI differs from earlier implementations because it focuses on processes rather than isolated outputs. A high-level objective, such as preparing a regulatory submission, investigating a safety signal, or supporting trial operations, can be broken into smaller tasks handled by specialized agents. Different agents may retrieve data, analyze requirements, draft content, or perform quality checks, while a supervisory layer maintains context and escalates uncertainty for human review.
Connecting information across development
Connecting expertise, data, and AI can help information flow more effectively across functions throughout the development lifecycle. In clinical development, agentic systems can support protocol design and feasibility by aggregating and assembling fragmented data into coherent evidence packs for expert review.
Consider a practical example: a protocol development team might use agents to retrieve historical recruitment performance across sites, compare eligibility criteria against previous studies in similar populations, identify operational risks based on site capabilities, and prepare draft feasibility assessments. The agent surfaces inconsistencies – for example, if a protocol requires niche expertise at sites with no prior experience – and flags priorities that require expert attention. The development team then reviews, refines, and makes final decisions based on their experience and strategic priorities.
During study startup and execution, agentic AI can help identify missing operational inputs before they affect timelines. Agents can proactively query systems to surface incomplete site qualifications, highlight recruitment performance against projections, monitor protocol adherence patterns, and escalate emerging risks. This reduces the manual work of coordinating across fragmented systems and catches problems earlier when they are easier to address.
In pharmacovigilance, agents can retrieve relevant case information, aggregate commonalities, draft structured narratives identifying what is known and unknown, and flag critical missing data for expert review. Regulatory teams can use them to assemble submission packages, track document completeness, identify inconsistencies, and support content development. In both cases, the technology reduces manual work while preserving human accountability for scientific interpretation and decision-making.
Workflow design matters as much as model performance
Work on early agentic AI applications has highlighted a critical reality: success depends as much on how workflows are designed as on how well models perform. Poorly defined objectives, fragmented source data, and unclear escalation paths can produce outputs that sound plausible but are operationally or scientifically flawed.
The real value emerges from combining three elements: clearly defined processes, connected data sources, and human expertise at the right decision points. In our work, success has depended as much on workflow redesign and change management as it does in the technology. Our experience suggests agentic systems deliver greatest value when positioned as tools that enable more effective workflows, rather than replacements for them.
This shift is significant. Rather than asking what AI can do, the question becomes: “what should we redesign in our workflow to make this more effective?”
Governance in regulated environments
Agentic AI is likely to deliver the greatest value in complex, information-rich workflows governed by clear processes and requirements. But in regulated environments, we have found that governance works best when embedded from the outset.
This means establishing clear audit trails for what agents retrieve, generate, and recommend; maintaining evidence packs that show how intermediate outputs were assembled and what data informed them; and defining agent identity and traceability so that downstream reviewers understand which system produced which output.
Decision documentation in an agentic workflow looks different than traditional audit trails. Rather than recording a single decision point, it captures a sequence: what the agent retrieved and why, what it generated or recommended, where and how it flagged risks or inconsistencies, and critically, where human judgement was applied. For example, if an agent recommends against a site based on historical recruitment data, the documentation should show the data retrieved, the reasoning presented to the expert, and the expert's decision (whether they accepted or overrode the recommendation and why). This maintains the scientific accountability while preserving the efficiency that agents provide.
To illustrate how this works, consider how the handoff might unfold across key use cases:
Protocol feasibility: an agent assembles historical recruitment data, compares site capabilities, and surfaces risks (e.g. ‘This site successfully enrolled similar patients 18 months ago but has had no similar studies since’). The development team reviews the evidence pack, applies their strategic knowledge of current site relationships and capabilities, and makes the final site selection decision.
Safety signal investigation: an agent retrieves relevant cases from multiple systems, identifies commonalities, drafts a structured narrative highlighting what's known and unknown, and flags critical missing data. A pharmacovigilance specialist reviews the agent’s work, confirms the assessment is scientifically sound, and decides whether escalation is warranted.
Regulatory submission readiness: an agent tracks document completeness identifies inconsistencies between modules, and highlights sections that may need updates based on recent data. A regulatory affairs manager reviews the completeness assessment, confirms accuracy and consistency, and approves the submission package for final review.
Transparency, auditability, security, and human oversight must be treated as essential requirements from the start, not added later.
Agentic AI for scientific work
The growing volume of evidence is creating a role for agentic AI designed specifically to support scientific work. Beyond workflow coordination, agentic systems can search primary literature, analyse omics and real-world datasets, write analytical code, and help researchers evaluate experimental designs. By assembling and interpreting evidence from multiple sources, they help teams assess hypotheses more efficiently – particularly when developing genomically targeted or platform-based therapies.
These analytics agents operate within the same governance framework as workflow agents: they support and accelerate scientific thinking but do not replace it. Scientists remain responsible for formulating hypotheses, interpreting evidence, and deciding how to act on findings.
The timing is particularly significant. Advances in genomic sequencing, CRISPR-based editing, mRNA and other nucleic acid platforms, and high-resolution multi-omic profiling have given scientists much greater ability to study and manipulate biological systems. They have also produced volumes of evidence that no team can review or reconcile unaided. Connecting these various sources of information and interpreting them in context has therefore become a major challenge for development teams. Agentic systems built for this purpose could help significantly – if they are designed with the understanding that they are supporting human judgement, not replacing it.
Looking forward
The value of agentic AI in pharma will depend on how effectively organizations combine human expertise, connected data, appropriate governance, and well-designed workflows. Its immediate contribution is helping teams manage increasingly complex information and processes while keeping scientific interpretation and accountability with people.
The stakes for getting this right are significant. As pharmaceutical research generates exponentially more data – from genomic sequencing, multi-omic profiling, real-world evidence, and emerging analytical technologies – the human challenge shifts from having too little information to having too much, and from too many isolated systems to keeping them connected. Agentic AI, properly implemented, can help development teams navigate that complexity.
The companies best positioned to compete are likely those that treat agentic systems not as replacements for expertise, but as force multipliers for it – tools that free experts from administrative burden and fragmented processes, so that they can focus on what they do best: scientific judgement, risk navigation, and decision-making.
